Pharmaceuticals
-
Europe moves against colistin misuse
New European rules could restrict the use of the antibiotic colistin on farms, it was announced yesterday. Read more
-
Europe-wide e-cigarette study released
The rate of e-cigarette use is increasing across Europe – alongside the belief that they are harmful, according to an analysis published today. Read more
-
Aspirin reduces risk of major stroke
Taking an aspirin immediately after suffering a minor stroke could be key to reducing the risk of having a major stroke in the ensuing days, according to researchers. Read more
-
Global call to tackle antimicrobial resistance
Britain should support international efforts to tackle antimicrobial resistance before it leads to millions of deaths, according to a major report published today. Read more
-
Hallucinogenic may benefit depression
The hallucinogenic compound in "magic" mushrooms could form the basis of new treatments for depression, researchers reported today. Read more
-
Belgian hope for HIV treatment
A treatment which stops HIV from replicating has shown promise in the laboratory, Belgian researchers have reported. Read more
-
Low dose alteplase boosts stroke survival
A reduced dose of alteplase cut rates of intracerebral haemorrhage and improved patient survival, according to the results of a major clinical trial published yesterday. Read more
-
Caution over NICE cholesterol drug recommendation
A leading medical charity has urged caution today after the UK regulator NICE recommended two new medications for people with cholesterol conditions that put them at increased risk of heart attack or stroke. Read more
-
AF statin guidelines could change following trial
International guidelines on preventing atrial fibrillation could change after a major trial raised questions about the benefits of taking statins before and after heart surgery. Read more
-
Hope for quick and cheap antibiotic
A fast and cheap method of producing a promising antibiotic that could treat superbugs has been developed for the first time. Read more
